FDA dubs Acadia Parkinson's drug Nuplazid 'breakthrough'
This article was originally published in Scrip
Executive Summary
Shares of Acadia Pharmaceuticals jumped 13% in morning trading on 2 September on word it had received the FDA's breakthrough therapy designation for the firm's investigational Parkinson's disease psychosis drug Nuplazid (pimavanserin).